Liu J, Zhang X, Cheng Y, Cao X. Dendritic cell migration in inflammation and immunity. Cell Mol Immunol. 2021;18:2461–71. https://doi.org/10.1038/s41423-021-00726-4.
Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17:30–48. https://doi.org/10.1038/nri1256.
Li X, Li J, Li G, Zhu L, Cheng G, Li H, et al. Engineered immunosuppressive dendritic cells protect against cardiac remodeling. Nature. 2026; https://doi.org/10.1038/s41586-026-10346-5.
Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91–6. https://doi.org/10.1126/science.abm0594.
Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430–3. https://doi.org/10.1038/s41586-019-1546-z.
Du H, You X, Zhang J, Liu S, Zhou Y, Wang Y, et al. CAR macrophages engineered in vivo for attenuating myocardial ischemia‒reperfusion injury. Circ Res. 2025;137:846–59. https://doi.org/10.1161/CIRCRESAHA.125.326716.
Wang J, Du H, Xie W, Bi J, Zhang H, Liu X, et al. CAR-macrophage therapy alleviates myocardial ischemia‒reperfusion injury. Circ Res. 2024;135:1161–74. https://doi.org/10.1161/CIRCRESAHA.124.325212.
Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T-cell therapies for cancer treatment. eBioMedicine. 2024;106:105266. https://doi.org/10.1016/j.ebiom.2024.105266.
Castenmiller C, Keumatio-Doungtsop B-C, van Ree R, de Jong EC, van Kooyk Y. Tolerogenic immunotherapy: targeting DC surface receptors to induce antigen-specific tolerance. Front Immunol. 2021;12:643240. https://doi.org/10.3389/fimmu.2021.643240.
Busek P, Mateu R, Zubal M, Kotackova L, Sedo A. Targeting fibroblast activation protein in cancer–prospects and caveats. Front Biosci. 2018;23:1933–68. https://doi.org/10.2741/4682.